Modern Meadow, CytoVale and Bell Biosystems close Series A rounds
We’re proud to report that three Breakout Labs companies have reached a major milestone on the path from the lab to the economy. We fund companies to take those first steps toward the marketplace with the understanding that there’s a long road ahead. Considering it’s only been two years since we made our first investments, it’s incredibly rewarding to see these innovators raise the money they need to reach the next level in their development.
Modern Meadow, a Brooklyn-based startup that specializes in a tissue engineering technique known as “biofabrication,” received a $10 million investment from Horizons Ventures. By growing leather from skin cells and biofabricating meat from muscle cells, the company hopes to help reduce the impact on livestock and the environment. Read the full story in The Wall Street Journal.
With investments from Dolby Family Ventures and NetScientific, Cytovale has raised a $4.3 million Series A round. The new funding will allow the South San Francisco-based startup to develop technology that enables early detection of sepsis, a serious reaction to infection that can lead to lung, kidney and liver failure. Read the full story on Venturewire.
Bell Biosystems Inc., a synthetic biology startup based in San Francisco, raised a $3 million Series A round with funding from LiteCap and 19 other investors. Bell Biosystems develops synthetic organelles that create magnetic nanoparticles. These “magnelles” allow researchers to track therapeutic cells when they’re introduced into living organisms. Read the full story on Venturewire.